Anthony D Harries Ministry of Health, Malawi

Slides:



Advertisements
Similar presentations
Scaling up HIV services for women and children achievements and challenges e-lluminate session e-lluminate session Yves Souteyrand 2 March 2010.
Advertisements

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.
Strategic Information for Anti-RetroViral Treatment Programmes Workshop WHO and UNAIDS Geneva June 30- July Ties Boerma HIV Department Surveillance,
Cotrimoxazole prophylaxis in HIV positive TB patients Rhehab Chimzizi Anthony Harries Ministry of Health-Malawi.
Group III: Demand Forecasting
TB/HIV Research Priorities: TB Preventive Therapy.
Tuberculosis in Children: Prevention Module 10C - March 2010.
The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.
Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.
Dr Tin Tin Sint Department of HIV/AIDS World Health Organization
PROGRAMMATIC OPERATIONAL RESEARCH DEVELOPMENT OF MALAWI’ S POLICY ON COTRIMOXAZOLE PREVENTIVE THERAPY R. Zachariah / AD Harries Contacts:
Why we shouldn’t (yet) move to TDF/FTC as the primary first line regimen for PEPFAR-supported programs Barbara Marston, M.D. Care and Treatment Team, GAP,
Prevention of Mother-to-Child Transmission of HIV in Ghana
Unit 5: IPT Isoniazid TB Preventive Therapy
Chronic HIV Infection Clinical Manifestations Opportunistic Infections O.I. Prophylaxis.
PMTCT at Different Levels of Care: The Uganda Experience Dr. Saul Onyango National PMTCT Coordinator Ministry of Health 1 1.
“Don’t tell me TB is under control!” Understanding TB
PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV WHAT’S NEW Prepared by Dr. Debbie Carrington National HIV/AIDS Prevention & Control Programme Ministry.
Increasing HIV treatment for TB patients – thinking out of the box Anthony D Harries, The Union Paris, France.
WHO technical recommendations on pediatric HIV care Summary of revised recommendations on diagnosis, clinical staging & immunological classification, &
Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.
JNB/05 HIV/AIDS treatment - challenges in a remote rural area of Tanzania. Johan N. Bruun Department of Infectious Diseases Ullevål University Hospital.
1 Guidance on Cotrimoxazole Prophylactic Therapy for HIV Exposed/Infected Children HAIVN Harvard Medical School AIDS Initiative in Vietnam.
2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.
1 Starting ART in the Context of Opportunistic Infections HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Office of Overseas Programming & Training Support (OPATS) Treatment Adherence HIV Care, Support, and Treatment.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Prophylaxis of Opportunistic Infections
HIV Testing for TB Patients in the Context of ART Scale-Up - Barriers to Implementation Kevin M. De Cock, MD CDC Kenya Geneva, February 14, 2005.
1 Management, Care for infants who were born from infected mothers HAIVN Harvard Medical School AIDS Initiatives in Vietnam.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Starting ART in the setting of Opportunistic Infections in children
PMTCT around the world Where are we? PMTCT Experts Roundtable Geneva, June 2008.
A Call to Action Children – The missing face of AIDS.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Diagram: Four stages of PMTCT Primary prevention of HIV Antenatal Care Labour and delivery Postnatal Care.
PMTCT 365 Days of Action to end the hidden violence against women and children Protecting Women early.
1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
OVERVIEW OF PREVENTING MOTHER TO CHILD TRANSMISSION OF HIV
TREATMENT OF HIV.
Participants 18year old+
Update on Breastfeeding and HIV studies
On behalf of The MTN-020/ASPIRE Study Team
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Treatment of Latent TB Infection (LTBI)
Dr Dawood Quiz questions.
The importance of TB and HIV programme collaboration and expanding the scope of collaboration for the future. 20 min. George Loth WHO/HIV/SRM.
The use of cotrimoxazole prophylaxis in the context of HIV infection
New regimen for $75 a year New pricing agreement will speed up access to generic, dolutegravir (DTG)-based fixed dose combinations (FDCs)  HIV positive.
World Health Organization
PHARMACOTHERAPY III PHCY 510
Thokozani Kalua MBBS MSc Malawi Ministry of Health
Charles Gilks HIV Department, WHO
Dr Immaculate Kariuki Consultant Paediatrician Nairobi, Kenya
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Tuberculosis Global Epidemiology
Indian Scenario HIV Situation TB Situation
When to START During an OI
Switch to LPV/r monotherapy
Cotrimoxazole Prophylaxis in HIV positive individuals Group A
monitoring & evaluation THD Unit, Stop TB department WHO Geneva
Monitoring of Antiretroviral therapy (ART)delivery by Regional Tuberculosis Officers (RTO) in Malawi: Rhehab Chimzizi Anthony Harries Edwin Libamba Maxwell.
Latent TB Infection (LTBI)
Preventing recurrent TB in high HIV-prevalent areas
Strategic framework for TB/HIV
HUMAN IMMUNODEFICIENCY VIRUS (HIV) PREVENTION & CARE
The IAS TB/HIV Research Prizes are awarded to:
Presentation transcript:

Anthony D Harries Ministry of Health, Malawi Cotrimoxazole and INH preventive therapies in the era of ART: are they necessary? Anthony D Harries Ministry of Health, Malawi

I DO NOT KNOW!

Cotrimoxazole

COTRIMOXAZOLE (CTX) PROPHYLAXIS Useful against:- Pneumocystis jiroveci (carinii) pneumonia Toxoplasma encephalitis Isospora belli diarrhoea Some bacteria and enterobacteria Nocardiosis Falciparum malaria

CTX prophylaxis in HIV+ve persons in industrialised countries Patients with CD4 counts < 200/mm3 to prevent PCP and other opportunistic infections Patients who have had an episode of PCP or toxoplasma encephalitis Children born to HIV-positive mothers

UNAIDS Recommendations for CTX prophylaxis in Africa HIV positive adults with:- WHO Stage II, III or IV disease CD4 counts of 500/mm3 or less HIV-exposed infants from six weeks of age (particularly any child born to an HIV-infected woman)

Advantages of CTX use Widely available, even in rural Africa Easy to take Relatively safe Does not require laboratory monitoring Effective during 2 year follow-up periods Cheap [costs 6 – 12 USD per year]

CTX Prophylaxis Industrialised Countries Widely used Main use to prevent PCP in adults with CD4 count < 200/mm3 and children born to HIV+ve mothers Can be discontinued in those on ART if CD4 count rises to > 200/mm3 Sub-Saharan Africa Infrequently used Main effect is to prevent diarrhoea and malaria in adults and PCP in children Reduces mortality, particularly in those with WHO Stage III and IV and patients with TB

CTX use in HIV-positive adults in Africa: before starting on HAART Indications for CTX: WHO Stage II disease CD4 count > 350/mm3 TB patients on RH-regimens with R-NVP interactions Eligible patients waiting to start ART Comment: Maybe less effective May not be needed if NVP is replaced by EFV in ART regimen Relieves anxiety and may prevent OIs

CTX use in HIV-positive adults in Africa: for patients on HAART Advantages Takes time for CD4 counts to rise, and may protect against infections in this interim period May prevent malaria and diarrhoea even in those with good CD4 counts Disadvantages Adds to the number of pills and may compromise good adherence Increases the risk of drug-induced toxicity Increases expense May increase risk of resistance to anti-malarial drugs (S-P)

CTX use in children born to HIV-positive mothers in Africa Advantages: From 6 weeks (up to when HIV infection can be ruled out) may prevent PCP Difficult to diagnose HIV in infants Difficult to determine if HIV-infected children are eligible for ART (need to measure CD4%) Difficult to administer ART to infants Question marks: Duration of prophylaxis in children? Will over-treat a considerable number of children, particularly if PMTCT programmes are operating well

The main question: “Is CTX necessary in patients taking ART in Africa WE DO NOT KNOW Therefore, the ways forward:- Randomised controlled trial of CTX versus placebo in HIV-positive patients (TB and non-TB) commenced on HAART In well run ARV programmes and TB programmes, assess use of CTX in the routine system against standardised outcomes

Isoniazid Preventive Therapy

Background: Isoniazid HIV infection is strongest risk factor for reactivation of TB in persons with latent TB [5 – 15% HIV+ve persons develop TB per year] Isoniazid reduces risk of TB in HIV-positive persons: [rate reduction of 0.4 in HIV+ve, PPD not determined] [rate reduction of 0.6 in HIV +ve, PPD +ve] Isoniazid reduces the risk of recurrent TB in HIV+ve TB patients who have completed a course of anti-TB treatment

Background: ART ART improves cell mediated immunity and reduces the risk of TB in HIV-positive persons ART reduces TB risk most in patients with WHO Stage III or IV disease and in those with CD4 counts < 200/mm3 ART may reduce risk of recurrent TB in HIV+ve patients completing TB treatment

Use of Isoniazid to prevent TB Given as dose of 300 mg daily: 6-12 months Relatively safe Generally well tolerated Does not promote INH drug resistance Effect lasts 1 – 2 years and then risk of TB gradually returns Need to be able to screen persons for TB before starting INH INH preventive therapy not widely used in Africa because of difficult logistics

Value of Isoniazid Useful as a measure to prevent TB for HIV-positive individuals, either first time TB or recurrent TB Not useful as a measure to reduce the burden of TB in high HIV burden communities because:- - need to have large numbers of people HIV tested - small % of HIV+ve persons complete the course - lack of structures to manage INH preventive therapy

Use of INH in era of ART: HIV-positive persons in WHO Stage I and II ART is not indicated in such persons INH therefore has potential benefit One possible structure in which to introduce INH is the PMTCT programme Risk of TB in Stage I and II may not be as high as in later stages, and therefore the cost-benefit of INH may be muted

Use of INH in era of ART: HIV-positive persons in Stage III and IV Logistics and advantages: ART is indicated in such patients INH may be more useful to give in Stage III/ IV patients (with no TB) For those on ART, there should be a regular structure for follow-up of patients and therefore INH adherence may be better Problems: May be difficult to exclude TB in these patients, especially stage III disease INH may add to toxicity of ARV drugs, especially stavudine (d4T) Extra pills to take and this may compromise adherence

Use of INH in era of ART: HIV+ve TB patients who completed TB treatment ART is indicated in such patients ART should reduce the risk of TB by increasing cell mediated immunity, although not to the extent of being HIV-negative: (in Cape Town, ART reduced incidence of new TB from 9.7% to 2.4% per annum) INH may provide additional benefit

Research questions on INH Does PMTCT provide a suitable structure for INH preventive therapy in HIV-positive persons in Stage I or II? Does the addition of INH to ART further reduce the incidence of new TB and recurrent TB in HIV-positive patients in Stage III and IV?